Intravenous Zoledronic Acid in Postmenopausal Women with Low Bone Mineral Density

2002875 citationsJournal Articlebronze Open Access

Authors

Ian R. Reid · University of Auckland

Jacques P. Brown · Centre hospitalier de l'Université Laval

P. Burckhardt · University Hospital of Lausanne

Zebulun D. Horowitz

Peter Richardson

U. Trechsel · Novartis (Switzerland)

A. Widmer · Novartis (Switzerland)

J.-P. Devogelaer

Abstract

Zoledronic acid infusions given at intervals of up to one year produce effects on bone turnover and bone density as great as those achieved with daily oral dosing with bisphosphonates with proven efficacy against fractures, suggesting that an annual infusion of zoledronic acid might be an effective treatment for postmenopausal osteoporosis.

Topics & Keywords

Bone health and osteoporosis research Bone health and treatments Bone and Joint Diseases

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 346, Issue 9, pp. 653-661

DOI: 10.1056/nejmoa011807

Field-Weighted Citation Impact: 65.02